FP6Отличие2004–2007

ED-REG-HAR · Ethical diversity and regulatory harmonisation: an empirical exploration of research ethics committees following the directive on good clinical practice

6РП — Действия „Мария Кюри“

Период
2004-10-01 → 2007-09-30
Финансиране от ЕС
1 076 871 €
Участници
1
Схема
EXT

Линиите свързват координатора с партньорите.

Накратко на български

Етичните комисии в Европа се изследват чрез наблюдения и интервюта, за да се разбере как оценяват протоколите за клинични изпитвания. Това помага да се установи кои разлики в оценките се дължат на местната култура и как да се създадат общи добри практики.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Final Activity Report Summary - ED-REG-HAR (Ethical diversity and regulatory harmonisation: an empirical exploration of research ethics committees following the Directive on Good Clinical Practice)

The project has completed all its main objectives including: -to explore the way in which IECs assess clinical trials protocols for ethical suitability; - to assess which variations are necessarily a consequence of local cultural differences, and which are not; - to highlight the way in which European pharmaceutical harmonisation can incorporate ethical diversity and develop best practice for IECs. The members of the research team carried out the following work: - Hungary: observations of 14 meetings (between 1 and 4 hours long) at 3 committees over 12 months. Interviews with 50 people: including 18 committee members, 7 commentators, 3 policy makers, 2 industry representatives, 5 researchers and 3 patient group representatives. - Sweden: observation of 23 meetings (3-4 hours long) at 6 different regional EPNs. 62 interviews with 24 EPN members (from 3 committees), 14 administrators, 4 policy makers, 5 commentators, 4 industry representatives, 6 researchers, and 2 representatives of patient groups. - Portugal: Observation of 50 meetings at central ethics committee in Lisbon (each between 3 and 7 hours) and 7 meetings at local ethics committees (each between 2 and 3 hours). A total of 74 interviews with: 56 members of the central and local ethics committees; 6 policy makers; 7 representatives of pharmaceutical companies; 2 politicians; 4 researchers; 4 representatives of patients groups. United Kingdom: 32 observations of committee meetings (each 3-4 and 1/2 hours long); 58 interviews with REC members (37 interviews), industry representatives (6 interviews), policy-makers (8 interviews) and other interested parties (7 interviews). This project created a highly interdisciplinary team, which explored an area of research which has been largely neglected by social scientists and policy-makers, using a multi-national, empirically based comparative study of ethics decision-making. This project has allowed the Team leader to develop his research interest in an under-explored area, and to consolidate the research experience he has gained in his PhD and postdoctoral fellowship. Team members gained experience of small-team work which is unusual in the social sciences, and consolidated PhD and previous postdoctoral work, as well as developing new research skills.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The aims of this project are: to explore the way in which Independent Ethics Committees (lECs) assess clinical trials protocols for ethical suitability; to assess which variations are necessarily a consequence of local cultural differences, and which are not; to highlight the way in which European pharmaceutical harmonisation can incorporate ethical diversity and develop best practice for lECs.As a result of the Directive on Good Clinical Practice (GCP), since the 1st of May 2003 Independent Ethics Committees have had a statutory role under European Legislation in the ethical assessment of clinical drugs-trials. This is part of a general move towards the harmonisation of pharmaceutical regulations, both worldwide and within Europe (e.g. the setting up of the EMEA).But there is a largely unexplored tension between this drive towards harmonisation, now seen in ethical review, and the important role cultural and ethical diversity plays within Europe. For example, even within a single member state (the UK), there has bee n considerable tension between the requirement that clinical trials be assessed by ethics committees and the range and diversity of opinion such committees have, even regarding the same clinical trial.This problem will be magnified at the European level. This project will use qualitative methods to compare the decision-making processes of ethics committees in four different countries (UK, Sweden, Portugal and Hungary). The team will recruit a researcher from each of these countries, showing a high degree of mobility.In its analysis the team will use dimensions of comparison such as: differing interpretations of what is meant by informed consent; the relationship between need for technical ability to understand material and the democratic principle of lay members; and the influence of different cultural/social factors (e.g. religious traditions;

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз